Aisling Capital Management LP
NEW YORK NY · SEC CIK 0001766721
$4.76亿2026Q1 申报市值
13持仓数
99.5%前十大占比 · 第一大 79.4%
1 / 1新建仓 / 清仓
26Q126Q2
前十大持仓 占组合比例
2026Q1 买入最多 按季末市值估算
BBOT 加仓+$405.79万
EPRX 新建仓+$235.30万
GLUE 加仓+$137.08万
CMPS 加仓+$129.36万
2026Q1 卖出最多 按季末市值估算
CalciMedica, Inc 清仓-$343.41万
2026Q1 持仓明细 点表头排序
导出 CSV 🔒| 代码 | 名称 | 市值 ▲ | 占比 | 股数 | 变动股数 | 变动 | 估算买卖额 | 操作 |
|---|---|---|---|---|---|---|---|---|
| — | CalciMedica, Inc. (CALC) | $0 | 0.00% | 0 | -521,114 | -100.0% | -$343.41万 | 清仓 |
| OKUR | OnKure Therapeutics, Inc. (OKUR) | $36.68万 | 0.08% | 88,607 | 0 | 0.0% | — | 不变 |
| — | Marker Therapeutics, Inc. (MRKR) | $42.30万 | 0.09% | 325,370 | 0 | 0.0% | — | 不变 |
| ACRS | Aclaris Therapeutics Inc (ACRS) | $162.92万 | 0.34% | 434,455 | 0 | 0.0% | — | 不变 |
| URGN | Urogen Pharma Ltd. (URGN) | $194.18万 | 0.41% | 108,000 | 0 | 0.0% | — | 不变 |
| EPRX | Eupraxia Pharmaceuticals Inc. (EPRX) | $235.30万 | 0.49% | 325,000 | 325,000 | — | $235.30万 | 新建仓 |
| — | Biomea Fusion Inc (BMEA) | $313.46万 | 0.66% | 2,048,757 | 0 | 0.0% | — | 不变 |
| SRRK | Scholar Rock Holding Corporation (SRRK) | $378.68万 | 0.80% | 77,031 | 0 | 0.0% | — | 不变 |
| CMPS | Compass Pathways Plc (CMPS) | $792.08万 | 1.66% | 1,432,336 | 233,918 | 19.5% | $129.36万 | 加仓 |
| BBOT | BridgeBio Oncology Therapeutics (BBOT) | $911.13万 | 1.91% | 1,018,018 | 453,393 | 80.3% | $405.79万 | 加仓 |
| BCAX | Bicara Therapeutics Inc. (BCAX) | $1,131.58万 | 2.38% | 568,919 | 0 | 0.0% | — | 不变 |
| GLUE | Monte Rosa Therapeutics Inc (GLUE) | $2,559.07万 | 5.37% | 1,555,664 | 83,333 | 5.7% | $137.08万 | 加仓 |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $3,076.06万 | 6.46% | 1,316,806 | 0 | 0.0% | — | 不变 |
| BBIO | BridgeBio Pharma Inc. (BBIO) | $3.78亿 | 79.35% | 5,089,611 | 0 | 0.0% | — | 不变 |